uniQure (NASDAQ:QURE) Raised to "Hold" at Wall Street Zen

Wall Street Zen upgraded shares of uniQure (NASDAQ:QURE - Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday.

Other analysts have also issued reports about the stock. HC Wainwright reiterated a "buy" rating and set a $70.00 price target on shares of uniQure in a research note on Monday, April 21st. Cantor Fitzgerald raised shares of uniQure to a "strong-buy" rating in a report on Monday, May 19th. Wells Fargo & Company cut their price target on uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a report on Friday, February 28th. Chardan Capital reaffirmed a "buy" rating and set a $38.00 price target on shares of uniQure in a research report on Monday, May 12th. Finally, Guggenheim reaffirmed a "buy" rating and set a $28.00 price target on shares of uniQure in a research report on Monday, May 12th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $37.82.

uniQure Stock Up 2.2%

uniQure stock traded up $0.34 during midday trading on Friday, reaching $15.50. The company's stock had a trading volume of 1,120,119 shares, compared to its average volume of 1,896,907. The stock's 50-day simple moving average is $12.47 and its 200-day simple moving average is $12.73. The stock has a market capitalization of $849.03 million, a P/E ratio of -3.12 and a beta of 0.10. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51.

uniQure (NASDAQ:QURE - Get Free Report) last posted its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.25. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $1.57 million for the quarter, compared to analyst estimates of $5.93 million. On average, sell-side analysts expect that uniQure will post -3.75 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Christian Klemt sold 10,438 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $107,407.02. Following the completion of the sale, the chief financial officer now owns 217,730 shares of the company's stock, valued at $2,240,441.70. This represents a 4.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Matthew C. Kapusta sold 6,717 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $76,036.44. Following the completion of the transaction, the chief executive officer now owns 580,795 shares of the company's stock, valued at approximately $6,574,599.40. This represents a 1.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 49,762 shares of company stock valued at $521,973. Company insiders own 4.74% of the company's stock.

Institutional Investors Weigh In On uniQure

Institutional investors and hedge funds have recently bought and sold shares of the company. Avoro Capital Advisors LLC acquired a new stake in shares of uniQure during the fourth quarter valued at about $38,410,000. Vestal Point Capital LP grew its holdings in uniQure by 58.4% in the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock worth $50,801,000 after purchasing an additional 1,767,572 shares during the period. RTW Investments LP increased its position in uniQure by 8,936.3% in the 4th quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company's stock valued at $15,958,000 after buying an additional 893,625 shares in the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of uniQure by 81.3% in the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company's stock worth $31,282,000 after purchasing an additional 794,459 shares in the last quarter. Finally, Boxer Capital Management LLC bought a new stake in shares of uniQure during the fourth quarter worth about $13,245,000. Institutional investors own 78.83% of the company's stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.